Irbesartan/Hct Eg (Hydrochlorothiazide, Irbesartan)

Irbesartan/HCT Eg is used in the management of hypertension, a condition characterized by chronically elevated arterial pressure.

• Hypertension: provides effective blood‑pressure reduction and helps achieve target levels in patients with primary or essential hypertension.

• Irbesartan selectively blocks angiotensin II binding to the AT1 receptor, preventing vasoconstriction, aldosterone release and sympathetic activation. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing natriuresis and diuresis, which together lower blood volume, peripheral resistance and arterial pressure.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pressure sensation.
• Fatigue: reduced energy or tiredness.
• Increased urination: due to diuretic action.
• Electrolyte imbalance: changes in potassium or sodium levels.
• Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels.
• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Pancreatitis: inflammation of the pancreas with abdominal pain.
• Blood dyscrasias: rare blood cell abnormalities.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: regularly assess to avoid excessive lowering.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Electrolyte surveillance: check potassium and sodium levels periodically.
• Hepatic impairment: use with caution in severe liver disease.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/HCT Eg may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Aliskiren: combined renin‑angiotensin blockade can cause severe hypotension and renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.
• ACE inhibitors or other ARBs: additive effect on blood pressure and renal function.
• NSAIDs: may blunt antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to prevent excessive hypotension.
• CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can increase irbesartan plasma concentrations.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irbesartan effectiveness.
• Diuretics that affect potassium: monitor serum potassium levels.
• Antidiabetic agents: potential enhancement of hypoglycemic effect.